» Articles » PMID: 38031150

Evaluation of Causal Associations Between Interleukin-18 Levels and Immune-mediated Inflammatory Diseases: a Mendelian Randomization Study

Overview
Publisher Biomed Central
Specialty Genetics
Date 2023 Nov 29
PMID 38031150
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Altered interleukin (IL)-18 levels are associated with immune-mediated inflammatory diseases (IMIDs), but no studies have investigated their causal relationship. This study aimed to examine the causal associations between IL-18 and IMIDs.

Methods: We performed a two-sample Mendelian randomization (MR) analysis. Genetic variants were selected from genome-wide association study datasets following stringent assessments. We then used these variants as instrumental variables to estimate the causal effects of IL-18 levels on the risk of developing five common IMIDs: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), ankylosing spondylitis (AS), and psoriasis. We used the inverse variance-weighted (IVW) method as the primary analysis, with sensitivity analyses performed to avoid potential bias. Reverse-direction MR analyses were performed to rule out the possibility of reverse associations.

Results: We found that genetically determined higher circulating IL-18 levels were causally associated with a higher risk for SLE (P = 0.009; OR, 1.214; 95% CI, 1.049 - 1.404) and IBD (P < 0.001; OR, 1.142; 95% CI, 1.062 - 1.228), but found no significant associations of IL-18 with RA (P = 0.496; OR, 1.044; 95% CI, 0.923 - 1.180), AS (P = 0.021; OR, 1.181; 95% CI, 1.025 - 1.361), or psoriasis (P = 0.232; OR, 1.198; 95% CI, 0.891 - 1.611). In the reverse direction, no causal relationship existed between SLE or IBD and IL-18 levels. Globally, sensitivity studies using alternative MR methods supported the results that were robust and reliable. The Cochran's Q test, MR-Egger intercept, and MR-Pleiotropy RESidual Sum and Outlier excluded the influence of heterogeneity, horizontal pleiotropy, and outliers.

Conclusions: We have demonstrated that elevated IL-18 levels increase the risk of SLE and IBD but not RA, AS, or psoriasis. The results enhanced our understanding of IL-18 in the pathology of IMIDs.

Citing Articles

Epstein-Barr virus infection exacerbates ulcerative colitis by driving macrophage pyroptosis via the upregulation of glycolysis.

Ma C, Chen K, Li L, Jiang M, Zeng Z, Yin F Precis Clin Med. 2025; 8(1):pbaf002.

PMID: 40041420 PMC: 11878796. DOI: 10.1093/pcmedi/pbaf002.


Very Early-Onset IBD-Associated IL-18opathy Treated with an Anti-IL-18 Antibody.

Guha A, Diaz-Pino R, Fagbemi A, Hughes S, Wynn R, Lopez-Castejon G J Clin Med. 2024; 13(20).

PMID: 39458007 PMC: 11508724. DOI: 10.3390/jcm13206058.


Mendelian randomization analysis of psoriasis and psoriatic arthritis associated with risks of ulcerative colitis.

Pan J, Lv Y, Wang L, Chang X, Zhao K, Liu X Skin Res Technol. 2024; 30(7):e13795.

PMID: 38995229 PMC: 11242227. DOI: 10.1111/srt.13795.

References
1.
Jafari-Nakhjavani M, Abedi-Azar S, Nejati B . Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus. J Nephropathol. 2016; 5(1):28-33. PMC: 4790184. DOI: 10.15171/jnp.2016.05. View

2.
Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

3.
Przepiera-Bedzak H, Fischer K, Brzosko M . Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Int J Mol Sci. 2016; 17(8). PMC: 5000653. DOI: 10.3390/ijms17081255. View

4.
Liang R, Zheng L, Ji T, Zheng J, Liu J, Yuan C . Elevated serum free IL-18 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders. Lupus. 2022; 31(2):187-193. DOI: 10.1177/09612033211069853. View

5.
Perry D, Sang A, Yin Y, Zheng Y, Morel L . Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011; 2011:271694. PMC: 3042628. DOI: 10.1155/2011/271694. View